Derm Cases · Dermatology / Rheumatology
OSCE — photosensitive plaques and scarring alopecia: cutaneous lupus classification and first-line therapy
An 8-minute OSCE station on ACLE/SCLE/DLE spectrum, work-up for systemic lupus, photoprotection and hydroxychloroquine stewardship, drug-induced SCLE, and pregnancy anti-Ro counselling.
On this page
Study tools
Target exams
NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on ACLE/SCLE/DLE spectrum, work-up for systemic lupus, photoprotection and hydroxychloroquine stewardship, drug-induced SCLE, and pregnancy anti-Ro counselling.
Brief (to candidate)
A 34-year-old woman has annular polycyclic scaly plaques on the upper back and arms after sun exposure, mild arthralgia, and positive anti-Ro/SSA. She is considering pregnancy. A separate patient photo shows scarring discoid plaques on the scalp. You have 8 minutes to classify CLE, investigate for SLE, and manage including pregnancy counselling.
Candidate instructions
- Classify ACLE vs SCLE vs DLE (CCLE).
- Plan labs for systemic involvement.
- State first-line photoprotection + antimalarial therapy and monitoring.
- Identify drug-induced SCLE culprits.
- Counsel anti-Ro pregnancy risk (neonatal lupus/CHB).
- Address scarring alopecia urgency in DLE.
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Classification | ACLE (malar/acute), SCLE (annular/psoriasiform photosensitive, anti-Ro), DLE/CCLE (scarring, scalp/face); Düsseldorf framework for subtypes including tumidus, profundus, chilblain LE[1][2] |
| Systemic screen | ANA, ENA (Ro/La), dsDNA, C3/C4, FBC, creatinine, urinalysis; ACLE often tracks active SLE; SCLE may be skin-limited or SLE-associated[2][9] |
| Histology/DIF | Interface dermatitis, dermal mucin; lupus band (granular IgG/C3 at BMZ) on DIF supports diagnosis when indicated[1] |
| First-line Rx | Strict SPF 50+ photoprotection; hydroxychloroquine ≤5 mg/kg/day first-line with annual retinal screening; escalate MTX/MMF/anifrolumab/belimumab for refractory SLE-linked disease; thalidomide specialist option for refractory DLE[1][4][9] |
| Drug-induced | SCLE triggers include terbinafine, thiazides, calcium-channel blockers, TNF inhibitors — stop culprit[7] |
| Pregnancy | Anti-Ro/SSA: small risk neonatal lupus / congenital heart block; continue HCQ when appropriate; obstetric/fetal medicine co-management and fetal heart surveillance pathways[1][10] |
| Communication | DLE scarring alopecia is irreversible — treat early; smoking cessation (reduces antimalarial efficacy); clear follow-up |
Model key actions
- Diagnose SCLE phenotype with anti-Ro and screen for SLE organ involvement.[1][2]
- Start photoprotection + hydroxychloroquine with retinal monitoring; stop drug triggers if present.[4][7]
- Counsel pregnancy/anti-Ro risks and co-manage; treat DLE aggressively to limit scarring.[10]
Common errors
- Using high-potency topical steroids alone long-term without antimalarials/photoprotection.
- Missing urinalysis/systemic work-up.
- No retinal screening plan on hydroxychloroquine.
- Ignoring drug-induced SCLE.
- Inadequate anti-Ro pregnancy counselling.
References6ShowHide
- [1]Vale ECSD, Garcia LC. Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects. Anais Brasileiros de Dermatologia, 2023.PMID 36868923
- [2]Stull C, Sprow G, Werth VP. Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist. The Journal of rheumatology, 2023.PMID 36109075
- [4]Niebel D, de Vos L, Fetter T, et al. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions. American Journal of Clinical Dermatology, 2023.PMID 37140884
- [7]He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Current opinion in rheumatology, 2018.PMID 29870500
- [9]Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the Rheumatic Diseases, 2024.PMID 37827694
- [10]Wainwright B, Bhan R, Trad C, et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Dis Primers, 2020.PMID 31685414